Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: Gastroenterology. 2014 Apr 22;147(2):453–462.e7. doi: 10.1053/j.gastro.2014.04.021

Figure 6.

Figure 6

Antiviral activity of compound 23, a selective PI4KIIIα inhibitor30. (A) Kinetic analysis showing (left panel) a concentration-dependent bi-phasic response to compound 23 in the GLuc assay that measures GLuc secreted by cells replicating H77S.3/GLuc2a virus and (right panel) compound 23 inhibition of release of infectious H77S.3 virus. Results shown represent the mean ± s.e.m. from triplicate cell cultures. (B) Compound 23 inhibition of H77S.3 RNA synthesis measured by incorporation of 5-EU into nascent RNA between 2–12 hrs after addition of the compound to the culture medium as in Fig 4. Results shown represent the mean ± s.e.m. from replicate independent experiments.